69 -5 (79) 2025 - Said-Axmedova S.K., Yakubova M.M. - COVID-19 ASSOCIATED CAVERNOUS SINUS THROMBOSIS IN DIABETES MELLITUS: CLINICAL, NEUROLOGICAL, AND MOLECULAR GENETIC FEATURES

COVID-19 ASSOCIATED CAVERNOUS SINUS THROMBOSIS IN DIABETES MELLITUS: CLINICAL, NEUROLOGICAL, AND MOLECULAR GENETIC FEATURES

Said-Axmedova S.K. - Tashkent Medical Academy

Yakubova M.M. - Tashkent Medical Academy

Raxmatullaeva G.K. - Tashkent Medical Academy

Resume

The aim of the work: to study the clinical, neurological and molecular genetic features of COVID-19 associated cavernous sinus thrombosis in patients with diabetes mellitus. Materials and methods of the study: 147 patients with cavernous sinus thrombosis (CST) after coronavirus were studied. The patients were divided into groups: 1) the main group - patients with type 2 diabetes mellitus (DM), n=103, 2) the control group - without type 2 DM, n=44. Results: During the molecular genetic study, 2 alleles of the MTHFR gene (Ala and Val) and 3 genotypes Ala/Ala, Ala/Val, Val/Val were identified (see Table 1). When carrying the mutational homozygous genotype Val/Val, the risk and chance of the disease increases by OR=2.1 and OR=2.4 times (p˂0.05)

Key words: cavernous sinus thrombosis, hypercoagulability, Ala222Val (665C>T) polymorphism of the MTHFR gene

First page

344

Last page

349

For citation:Said-Axmedova S.K., Yakubova M.M., Raxmatullaeva G.K. - COVID-19 ASSOCIATED CAVERNOUS SINUS THROMBOSIS IN DIABETES MELLITUS: CLINICAL, NEUROLOGICAL, AND MOLECULAR GENETIC FEATURES//New Day in Medicine 5(79)2025 344-349 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Цинзерлинг В.А., Вашукова М.А., Васильева М.В. и др. Вопросы патоморфогенеза новой коронавирусной инфекции (COVID-19). Журнал инфекто- логии. 2020; 12 (2): 5—11. https://journal.niidi.ru/jofin/article/view/1041?locale=ru_RU
2. Bikdeli B, Madhavan MV, Jimenez D, et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-theArt Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-73. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. https://pubmed.ncbi.nlm.nih.gov/32311448/
3. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020 Sep 10;136(11):1330-41. doi: 10.1182/blood.2020007252
4. Nagashima S, Mendes MC, Camargo Martins AP, et al. Endothelial Dysfunction and Thrombosis in Patients With Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2404-7. Epub 2020 Aug 7. https://pubmed.ncbi.nlm.nih.gov/32762443/
5. Roy D, Ghosh R, Dubey S, et al. Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. Can J Neurol Sci. 2021 Jan;48(1):9-24. doi: 10.1017/cjn.2020.173. Epub 2020 Aug 5. https://pubmed.ncbi.nlm.nih.gov/32753076/
6. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020 Jun;80(6):607-13. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10. https://pubmed.ncbi.nlm.nih.gov/32283152/

   file

   download